SQZ Stock Price, News & Analysis

SQZ Biotechnologies (SQZ) has announced its first quarter 2022 financial results, highlighting significant developments. The FDA granted Fast Track Designation for the lead APC clinical candidate SQZ-PBMC-HPV and IND clearance to initiate a Phase 1/2 trial for the eAPC candidate targeting HPV16+ solid tumors. Total revenue for the quarter was $2.9 million, a decrease from $5.5 million in Q1 2021. R&D expenses rose to $17 million, and net loss increased to $21 million from $15.4 million in 2021. As of March 31, 2022, the company had $122.9 million in cash, sufficient to fund operations through mid-2023.

SQZ Biotechnologies (NYSE: SQZ) announced a live R&D investor event on May 19, 2022, from 4:05 - 5:30 p.m. ET, focusing on its point-of-care manufacturing system and its SQZ® TAC clinical development program for celiac disease, with an FDA application expected in early 2023. Collaboration with STEMCELL Technologies will be part of the discussion, alongside a fireside chat featuring notable experts from MIT and the company leadership. The event will be accessible both onsite and virtually, with a replay available afterward.

SQZ Biotechnologies (NYSE: SQZ) announced promising results from its point-of-care (POC) manufacturing platform, capable of producing cell therapies in under 10 hours. The company is collaborating with STEMCELL Technologies to develop a research-use-only (RUO) system that enhances access to cell engineering capabilities. SQZ plans to present data on its POC system and hematopoietic stem cell engineering at the 2022 ASGCT Annual Meeting on May 18. The technology aims to improve the accessibility and cost-effectiveness of cell therapies, supporting advancements in the field.

SQZ Biotechnologies (NYSE: SQZ) announced CEO Armon Sharei will present at the Bank of America Securities 2022 Healthcare Conference on May 10 in Las Vegas, NV, and at the H.C. Wainwright Global Investment Conference on May 25 in Miami, FL. Presentation details include:

• May 10: 5:00-5:30 p.m. ET
• May 25: 9:30-10:00 a.m. ET

Webcast links are available on the company's website, where replays will be accessible for 90 days. SQZ focuses on cell therapies for oncology, autoimmune, and infectious diseases.

SQZ Biotechnologies (NYSE: SQZ) announced that the FDA has granted Fast Track Designation for its lead therapy candidate, SQZ-PBMC-HPV, aimed at treating HPV16+ advanced solid tumors. This designation may accelerate development and review processes for treatments for serious diseases. The candidate has shown promise in early clinical data, demonstrating potential anti-tumor activity and favorable tolerability. The ongoing Phase 1/2 clinical trial includes monotherapy and combination therapy evaluations, targeting significant treatment opportunities in oncology.

SQZ Biotechnologies has reported significant preclinical advancements in its eAPC platform, which shows that mRNA-based expression of CD86, IL-2, and IL-12 markedly enhances CD8 T cell activity against diverse antigens, including HPV and KRAS. Data presented at the AACR 2022 Annual Meeting indicates effective T cell responses in humanized mouse models. The SQZ-eAPC-HPV candidate is currently undergoing a Phase 1/2 trial (COMMANDER-001) for HPV16+ tumors, demonstrating promising potential for improved patient outcomes through enhanced immune responses.

SQZ Biotechnologies (NYSE: SQZ) announced that CEO Armon Sharei will present at two upcoming conferences: the 21st Annual Needham Virtual Healthcare Conference on April 13 from 9:30-10:10 AM ET, and Chardan’s 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit on April 26 from 10:00-10:25 AM ET. Webcast details for both presentations are available on the company's investors' page. SQZ Biotechnologies is a clinical-stage biotech firm focusing on cell therapies across multiple areas, including oncology and autoimmune diseases.

SQZ Biotechnologies has published preclinical research demonstrating the effectiveness of its Tolerizing Antigen Carrier (TAC) platform in combating autoimmune diseases, particularly type 1 diabetes (T1D). The study shows that TACs effectively delayed the onset of T1D, reduced autoreactive T cells, and induced regulatory T cells. The company plans to submit an IND for celiac disease in H1 2023 and is developing a point-of-care manufacturing system for clinical trials. The findings suggest a significant potential for TACs in therapy for autoimmune diseases.

SQZ Biotechnologies has received a $2 million SBIR Phase II grant from the National Institute of General Medical Sciences to develop methods for reprogramming immune cells into dopamine-producing neurons. This innovative approach aims to offer a new treatment paradigm for Parkinson's disease, potentially eliminating the need for chronic immunosuppression. The company's proprietary Cell Squeeze technology may enable efficient cell engineering with significant therapeutic potential beyond Parkinson's, targeting conditions like Multiple Sclerosis and Type 1 diabetes.